Catheter Precision Inc.

07/30/2024 | Press release | Distributed by Public on 07/30/2024 15:08

Material Agreement Form 8 K

Item 1.01 Entry into a Material Definitive Agreement.

8% Short Term Promissory Note due August 30, 2024 (the "Note")

On July 25, 2024, the Jenkins Family Charitable Institute, a Louisiana charitable trust (the "Trust"), loaned $500,000 to Catheter Precision, Inc. (the "Company") in exchange for the Note. The Note has a maturity date of August 30, 2024, and bears interest at the rate of 8% per annum. David A. Jenkins, Executive Chair and Chief Executive Officer of the Company, was the Settlor and Initial Trustee of the Trust, and the current Trustee of the Trust is Mr. Jenkins' adult daughter.

This Note is in addition to the following 8% Short Term Promissory Notes due August 30, 2024, issued in connection with prior loans extended to the Company by Mr. Jenkins and FatBoy Capital, L.P., an entity controlled by Mr. Jenkins, as previously reported:

Date of Note

Holder

Principal Amount

May 30, 2024

David A. Jenkins

$500,000

June 25, 2024

FatBoy Capital, L.P.

$150,000

July 1, 2024

FatBoy Capital, L.P.

$250,000

July 18, 2024

FatBoy Capital, L.P.

$100,000

The Note and the debt evidenced thereby, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owing when due, material breach of representations or warranties by us (unless waived by the holder of the Note or cured within 10 days following notice) and/or certain events involving a discontinuation of our business or certain types of proceedings involving insolvency, bankruptcy, receivership and the like.

In addition to his roles as a director and officer of the Company, Mr. Jenkins and his affiliates beneficially own over 10% of the common stock of the Company, Series X Preferred convertible into over 800,000 shares of Company common stock (subject to certain conditions), stock options issued by the Company, and the rights to receive royalties on sales of our LockeT device equal to an aggregate 11.77% of net sales, as defined in the relevant agreements. Mr. Jenkins is a co-inventor of certain of our products and has previously assigned his rights in relation to those inventions to us. In addition, Missiaen Huck, Mr. Jenkins' adult daughter, serves as our non-executive chief operating officer. For additional information see also Certain Relationships and Related Party Transactions in our proxy statement filed May 16, 2024.

A copy of the Note is filed as Exhibit 10.1 to this Form 8-K and incorporated herein by reference.